PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of carcinLink to Publisher's site
 
Carcinogenesis. Sep 2010; 31(9): 1620–1626.
Published online Jun 16, 2010. doi:  10.1093/carcin/bgq124
PMCID: PMC2930802
Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer
Hiroshi Hirata, Yuji Hinoda,1 Mohd S. Zaman, Yi Chen, Koji Ueno, Shahana Majid, Christina Tripsas,2 Mary Rubin,2 Lee-may Chen,2 and Rajvir Dahiya*
Department of Urology, Veterans Affairs Medical Center and University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
1Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 7558505, Japan
2Department of Gynecology, Veterans Affairs Medical Center and University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
*To whom correspondence should be addressed. Urology Research Center (112F), Veterans Affairs Medical Center and University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA. Tel: +1 415 750 6964; Fax: +1 415 750 6639; Email: rdahiya/at/urology.ucsf.edu
Received March 31, 2010; Revised June 3, 2010; Accepted June 10, 2010.
Endometrial cancer (EC) is a steroid hormone-dependent cancer. Uridine 5′-diphospho-glucuronosyltransferase enzymes conjugate and detoxify endogenous and exogenous steroid hormones and environmental carcinogens. Among these enzymes, the function of UGT2B17 is unknown except for glucuronidation. The messenger RNA expression of UGT2B17 and myeloid cell leukemia-1 (Mcl-1) was significantly increased in EC tissues compared with matched normal endometrial tissues. Therefore, we focused on the function of UGT2B17 in EC. A total of nine patients with confirmed EC were enrolled in this study to investigate the expression of UGT2B17 and target genes. EC cell lines were used for functional tests including cell growth, invasion, apoptosis and cell cycle analyses. To find the target genes of UGT2B17, we performed microarray analysis to see which genes were upregulated or downregulated by UGT2B17-transfected cells. Functional analysis showed decreased numbers of viable cells and increased numbers of apoptotic cells in si-UGT2B17-transfected Ishikawa cells. Among microarray target genes, Mcl-1 was significantly downregulated in si-UGT2B17-transfected cells. We also found upregulation of Puma protein, a target of Mcl-1, in si-UGT2B17-transfected cells. This is the first report to show that UGT2B17 and Mcl-1 expression are upregulated in EC tissues and that UGT2B17 depletion induces inhibition of cell growth and apoptosis in EC cells through Mcl-1 downregulation.
Endometrial cancer (EC) is a common gynecological cancer in the USA (1). The metabolism of estrogens has been thought to play an important role in the development and pathogenesis of EC (2). Estrogens are activated by biosynthetic enzymes (phase I) and detoxified by conjugation enzymes (phase II) (2). The phase II conjugation reactions include glucuronidation, sulfation and glutathione and amino acid conjugation (3). Glucuronidation is catalyzed by uridine 5′-diphospho-glucuronosyltransferase enzymes (4). After conjugation by glucuronidation, the derivatives are excreted through the bile or urine. UGT proteins generally have been categorized into four subfamilies (UGT1A, UGT2A, UGT2B and UGT3) based on homology (4,5). The UGT1A gene complex is located on chromosome 2q37 and encodes nine members of the UGT1A family (6). The UGT2A and UGT2B genes are located on chromosome 4q13–4q21.1 (5,6). The UGT2A subfamily includes three members and UGT2B subfamily includes 12 members (6). The UGT3 family was recently identified and members of the UGT3 family are ~30% homologous to those of other UGT families (6). With regards to UGT proteins and EC, some investigators have performed polymorphism studies and found that some UGT polymorphisms were related to EC risk (7,8). It has been well understood that UGT proteins play an important role in glucuronidation of endogenous and exogenous compounds including steroid hormones. Therefore, the function of UGT proteins has focused on pharmacogenetics in breast cancer treatment with tamoxifen (selective estrogen-receptor modulator) (9,10). Conversely, the function and expression of UGT protein are not well understood in EC. Recently Nakamura et al. (11) investigated the expression level of UGT1A and UGT2B messenger RNA (mRNA) in human normal tissues and various cancer cells. In their study, UGT1A5, UGT2B4, UGT2B7, UGT2B11, UGT2B15 and UGT2B17 mRNA was expressed in normal uterus (11), but only UGT2B17 mRNA expression was expressed in EC Ishikawa cells (11). Several UGT enzymes are regulated by estrogen level but the expression of UGT2B17 mRNA was not stimulated after estradiol (E2) treatment in MCF-7 cells (12). Recently, our laboratory did a functional analysis of CYP1B1, which is also an estrogen metabolic enzyme, in EC and found that CYP1B1 upregulation plays a crucial role in endometrial carcinogenesis by targeting multiple pathways, suggesting that CYP1B1 inhibition in EC could be a useful therapeutic approach (13). This evidence suggested to us that UGT2B17 function may be independent from estrogen regulation and may play a role in endometrial oncogenesis. To test this hypothesis, we first used real-time reverse transcription–polymerase chain reaction (RT–PCR) to confirm the expression of UGT2B17 in EC and adjacent endometrial normal tissues using paired samples. It was found that the mRNA expression of UGT2B17 was significantly increased in EC tissues compared with matched adjacent normal tissues (8/9 = 89%). We then examined the expression of UGT2B17 in several EC cell lines (KLE, HEC-1-B and Ishikawa cells) in order to choose one best suited for functional analysis. Since the expression of UGT2B17 was observed only in Ishikawa cells, we used Ishikawa cells for further experiments (MTS, apoptosis, cell cycle and invasion assays) to identify the function of UGT2B17. In order to examine the function of UGT2B17 in EC cells, we knocked down its expression using a siRNA technique and compared the effects between si-‘negative control’ and si-UGT2B17-transfected Ishikawa cells. We also performed microarray analysis to identify genes related to UGT2B17 expression.
Clinical samples
A total of nine patients with pathologically confirmed EC were enrolled in this study (University of California, San Francisco). The pathology of all the patients was endometrioid adenocarcinoma. Patient information is as follows: stage IA (5), stage IB (2) and stage IIIA (2) and grade I (7) and grade II (2). Stage information was according to International Federation of Gynecology and Obstetrics (FIGO) stage. Samples were obtained from the patients after written informed consent was obtained at the University of California, San Francisco.
Cell culture
EC cells (KLE, HEC-1-B and Ishikawa cells) were maintained in D-MEM/F-12 media (4.5 g/l glucose) supplemented with 10% fetal bovine serum, 1× penicillin/streptomycin and incubated at 37°C in a humidified incubator with 5% CO2.
RNA and protein extraction
RNA was extracted from cell lines using a QIAamp RNA kit (QIAGEN, Valencia, CA). Tissue total RNA was extracted using a combination of TRIzol reagent (Invitrogen, Carlsbad, CA) and RNeasy columns (Qiagen). Fresh EC and adjacent normal endometrial tissues were homogenized in 1 ml TRIzol reagent. To digest DNA, the Qiagen RNase-Free DNase kit was used. RNA quality was assessed by the NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE) spectrophotometer. Extracted RNA was stored at −80°C until used. Cells were lysed with RIPA buffer (Pierce, Brebieres, France) containing protease inhibitors (Sigma, St Louis, MO). Protein quantification was done using a BCA protein assay kit (Pierce).
Knockdown of UGT2B17 mRNA in Ishikawa cells
Ishikawa cells express estrogen receptors and progesterone receptors. However, according to previous reports, proliferation of Ishikawa cells was not promoted after estrogen treatment (14). Therefore, we did not use estrogen for culture of Ishikawa cells. Ishikawa cells were transfected with UGT2B17 siRNA (si-UGT2B17; Invitrogen) or negative control siRNA [si-negative control (si-NC); Invitrogen] according to the manufacturer's instructions. Briefly, cells were grown in six-well plates and transfected individually with three siRNAs [HSS144421 (no. 1), HSS144422 (no. 2) and HSS144423 (no. 3)] at a concentration of 200 pmol/ well. The siRNAs sequences are as follows: siRNA-no. 1, forward; 5′-AACGGCAUCUGCCAGAAGGACAUCA-3′/reverse; 5′-UGAUGUCCUUCUGGCAGAUGCCGUU-3′; siRNA-no. 2, forward; 5′-CUUCACAGAGCUUUAUAUUAUAGUC-3′/reverse; 5′-GACUAUAAUAUAAAGCUC UGUGAAG and siRNA-no. 3, forward; 5′-AACAGAGAAGCGGAGACUGUACAGA-3′/ reverse; 5′-UCUGUACAG UCUCCGCUUCUCUGUU-3′. Transfection was performed with X-tremeGene siRNA Transfection Reagent (Roche Diagnosis, Basel, Switzerland).
Cell viability assay
Cell viability was measured with MTS (CellTiter 96 Aqueous One Solution Cell Proliferation Assay; Promega). Data are the mean ± SD of six independent experiments.
Apoptosis and cell cycle analysis
Cells (si-NC and si-UGT2B17) were trypsinized and washed once in complete medium centrifuged at 2000 r.p.m. for 5 min at 4°C and resuspend in ice-cold 1× binding buffer. Annexin V-FITC solution (10 μl) and 7-aminoactinomycin D viability dye (20 μl) were added to 100 μl of the cell suspensions. After incubation for 15 min in the dark, 400 μl of ice-cold 1× binding buffer was added. The apoptotic distribution of the cells in each sample was then determined using a fluorescence-activated cell sorting (Cell Lab QUANTA SC; Beckman Coulter, Fullerton, CA). The various phases of cells were determined using a DNA stain (4′,6-diamidino-2-phenylindole). Cell populations (G0/G1, S and G2/M) were measured using fluorescence and contrasted against cell volume. Data are the mean ± SD of four independent experiments.
Cell invasion assay
Cell invasion assay was performed with six-well BD Biocoat Matrigel invasion chambers as described previously (BD Biosciences, Bedford, MA). The cells (si-NC and si-UGT2B17) were resuspended to the upper chamber in triplicate. Cells migrating through the membrane were stained with HEMA3 (Fisher Scientific Company, Kalamazoo, MI) and counted with a microscope. Five random fields were chosen for each membrane, and the results were expressed as migrated cells per field.
Complementary DNA microarray and quantitative real-time RT–PCR in Ishikawa cells
Apoptosis-related genes were profiled with the Human RT2 Profiler™ PCR Array (http://www.superarray.com/microarrays.php). The RT2 first strand kit, which includes a proprietary buffer to eliminate any residual genomic DNA contamination in cell line RNA samples, was used to convert mRNA into complementary DNA. The manufacturer's instructions were strictly followed. To analyze the PCR Array data, we used an MS-excel sheet from the manufacturer's website. The PCR Array Data Analysis Web Portal was used to perform several calculations as follows: scatter plots, three-dimensional profiles and a volcano plot. Based on the scatter plot data (relative expression comparison between si-negative control-transfected and si-UGT2B17-transfected cells), we selected candidate genes whose expression levels were increased or decreased in si-UGT2B17-transfected cells compared with si-negative control cells (fold cutoff was 3.5). Data was normalized based on correcting all Ct (threshold cycle) values for the average Ct values of several constantly expressed housekeeping genes present on the array. Quantitative real-time RT–PCR was performed in triplicate to confirm the results of microarray analysis with an Applied Biosystems Prism 7500 Fast Sequence Detection System using TaqMan universal PCR master mix according to the manufacturer's protocol (Applied Biosystems, Foster City, CA). The TaqMan probes and primers were purchased from Applied Biosystems. Human glyceraldehyde 3-phosphate dehydrogenase was used as an endogenous control. Levels of mRNA expression were determined using the 7500 Fast System SDS software version 1.3.1 (Applied Biosystems).
Western blotting
Total protein (20 μg) was used for western blotting. Samples were resolved in 4–20% Precise Protein Gels (Pierce) and transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Fairfield, CT). The membranes were immersed in 0.3% skim milk in Tris-buffered saline containing 0.1% Tween 20 for 1 h and probed with primary polyclonal and monoclonal antibody against poly ADP-ribose polymerase (PARP) (#9532; Cell Signaling Technology, Denvers, MA, USA), cleaved PARP (#9546; Cell Signaling Technology), Bax (#2772; Cell Signaling Technology), Bcl-2 (#551097; BD Biosciences), Puma (#4976; Cell Signaling Technology), myeloid cell leukemia-1 (Mcl-1) (#4572; Cell Signaling Technology), Akt (#4691; Cell Signaling Technology), phosphorylating Akt (#4060; Cell Signaling Technology) and beta-actin (#2118; Cell Signaling Technology) overnight at 4°C. Blots were washed in Tris-buffered saline containing 0.1% Tween 20 and labeled with horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit antibody (Cell Signaling Technology). Proteins were enhanced by chemiluminescence (GE Healthcare) for visualization. The protein expression levels are expressed relative to beta-actin levels.
Statistical analysis
All statistical analyses were performed using StatView (version 5; SAS Institute, Cary, NC). A P-value of <0.05 was regarded as statistically significant.
UGT2B17 and Mcl-1 expression in EC and adjacent normal endometrial tissues
UGT2B17 expression was significantly higher in EC tissues compared with adjacent normal endometrial tissues in paired tissue samples (8/9 = 89%) (Figure 1). Mcl-1 expression was increased in four of nine EC tissue samples (Figure 2).
Fig. 1.
Fig. 1.
Expression of UGT2B17 mRNA in EC and adjacent normal uterus tissues. Expression levels of UGT2B17 mRNA in EC tissues and adjacent normal endometrial tissues (nine paired samples).
Fig. 2.
Fig. 2.
The mRNA expression level of Mcl-1 in EC and matched adjacent normal uterus tissues. Expression levels of Mcl-1 mRNA in EC tissues and adjacent normal endometrial tissues (nine paired samples).
UGT2B17 expression in EC cell lines and normal endometrial tissues
We analyzed UGT2B17 mRNA expression in three EC cell lines (KLE, HEC-1-B and Ishikawa cells). We did not detect UGT2B17 mRNA expression in KLE and HEC-1-B cells. Only Ishikawa cells exhibited UGT2B17 mRNA expression (Figure 3A).
Fig. 3.
Fig. 3.
Expression of UGT2B17 mRNA in EC cells (A) and the effect of si-UGT2B17 on Ishikawa cells (B and C). (A) UGT2B17 mRNA expression in three EC cell lines. (B) Effect of si-UGT2B17 (no. 3) on the expression of UGT2B17 mRNA (B) and protein (C) in Ishikawa (more ...)
UGT2B17 expression in Ishikawa cells (relative expression: 28) was high compared with endometrial normal tissues (relative expression: 1.0, 1.5) (Figure 3A).
siRNA transfection, MTS, invasion and fluorescence-activated cell sorting in Ishikawa cells
As UGT2B17 mRNA expression was found only in Ishikawa cells, we knocked down the mRNA of UGT2B17 in Ishikawa cells using a siRNA technique. We used three different si-UGT2B17s (no. 1, no. 2 and no. 3), among which si-UGT2B17 RNA no. 3 (HSS144423) was most effective in decreasing the expression of UGT2B17 in Ishikawa cells (Figure 3B). The knockdown effect was also confirmed by western blot (Figure 3C). Therefore, we used si-UGT2B17 no. 3 (HSS144423) for further experiments with Ishikawa cells (MTS, invasion and fluorescence-activated cell sorting) (Figure 4). We found inhibition of cell growth with si-UGT2B17 transfection by MTS assay (Figure 4A). However, there were no significant differences in invasion assays between si-NC- and si-UGT2B17-transfected cells (Figure 4B). We found a significantly higher number of apoptotic cells in si-UGT2B17-transfected cells compared with si-NC cells (P < 0.05) (Figure 4C and D). The mean cell number in the S and G2/M phases of the cell cycle was also significantly lower in si-UGT2B17-transfected cells, suggesting that si-UGT2B17 induced G1 arrest in Ishikawa cells (Figure 4E). Apoptosis and cell cycle assay was done at 48 h after 72 h of siRNA (si-NC or si-UGT2B17) transfection because the proliferation in si-UGT2B17-transfected Ishikawa cells was significantly inhibited at this point (MTS, 48 h).
Fig. 4.
Fig. 4.
Effect of si-UGT2B17 on Ishikawa cell growth (A), invasion (B), apoptosis (C and D) and cell cycle (E). (A) MTS assay, (B) invasion assay, (C and D) apoptosis assay, Annexin V-FITC and 7-aminoactinomycin D were measured by flow cytometry. Representative (more ...)
Complementary DNA microarray, quantitative real-time RT–PCR and western blotting in si-UGT2B17-transfected cells
We focused our study on apoptosis genes because we found growth inhibition and increased apoptosis in si-UGT2B17-transfected cells. We initially profiled apoptosis-related genes with the Human RT2 Profiler™ PCR Array. A human apoptosis complementary DNA microarray, which included 87 genes, was used in this study. A cluster gram is shown in Figure 4. Genes found to be differentially expressed were clustered using hierarchical cluster analysis to visualize the pattern of gene expression for each group. The heat map indicates that red represents highly expressed genes, whereas green represents under expressed genes; the black color on the heat map represents equal expression relative to control. Based on these microarray data, seven genes were identified as being either upregulated (six genes) or downregulated (one gene) in si-UGT2B17-transfected cells compared with si-NC-transfected cells using this microarray (threshold, 2.5) (Figure 5A; supplementary Table S1 is available at Carcinogenesis Online). Among the identified candidate genes, Mcl-1 mRNA expression was confirmed by real-time RT–PCR. Namely, the expression of Mcl-1, an anti-apoptotic gene, was significantly downregulated by si-UGT2B17 transfection (Figure 5B). We also confirmed protein expression level of this gene and found it to be significantly decreased in UGT2B17 knockdown (Figure 6).
Fig. 5.
Fig. 5.
Human apoptosis microarray clustergram using si-NC-transfected or si-UGT2B17-transfected Ishikawa cells (threshold 2.5) (A) and validation with real-time RT–PCR (B). (A) Microarray data are shown. The expression of six genes were altered in si- (more ...)
Fig. 6.
Fig. 6.
Protein expression in si-NC-transfected or si-UGT2B17-transfected Ishikawa cells. The protein expression of Mcl-1 was significantly decreased in si-UGT2B17-transfected Ishikawa cells, whereas Puma protein expression was increased.
To confirm increased apoptosis, we performed western analysis of PARP and cleaved PARP. As shown in Figure 5, significantly increased expression of cleaved PARP was found in si-UGT2B17-transfected Ishikawa cells. The expression of Bax, Akt and phosphorylated Akt proteins were not changed, however, expression of Puma was increased in si-UGT2B17-transfected cells.
The study of estrogen metabolic and conjugation enzymes have focused on the relationship between enzyme activity, polymorphism, cancer susceptibility and response to chemotherapy (8). Similar to other enzymes, there have been a number of polymorphism studies on UGT2B17 (15,16), and functional studies of UGT2B17 have been focused on the glucuronidation of endogenous and exogenous compounds including steroid hormones (1719). UGT2B17 is expressed in the liver and various extrahepatic tissues including testis, uterus, prostate and lung (19). Recently Nakamura et al. (11) investigated the expression of the UGT2B family in various normal tissues and observed UGT2B17 mRNA expression in normal endometrial tissues. However, there have been no reports comparing the expression level of UGT2B17 in EC tissues and adjacent normal tissues. Therefore, we looked at UGT2B17 mRNA levels in both EC tissues and matched normal endometrial tissues using real-time RT–PCR. Unexpectedly, UGT2B17 mRNA expression was significantly higher in EC tissues. Next, we also observed UGT2B17 mRNA expression in EC Ishikawa cells as previously reported (11) and used these cells for functional analysis of UGT2B17.
The UGT family is involved in the glucuronidation of endogenous and exogenous steroid hormones and detoxification of environmental carcinogens, and hence, low UGT expression or activity may increase the risk of various cancers including EC (20). However, we observed that UGT2B17 mRNA expression was higher in EC tissues than in adjacent normal tissues in this study. Given that UGT2B17 mRNA was not regulated by estrogen level in breast cancer MCF-7 cells (12), we hypothesized that UGT2B17 might have other functions independent of estrogen, which promote EC. To test this hypothesis, we knocked down UGT2B17 mRNA in Ishikawa cells with an siRNA and observed its effects on cell growth, invasion, apoptosis and the cell cycle. In si-UGT2B17-transfected Ishikawa cells, the number of viable cells was significantly decreased compared with si-negative control-transfected cells. In addition, the number of cells in the apoptotic and G0/G1 phase was significantly increased after si-UGT2B17 transfection. The expression level of cleaved PARP was also significantly increased in si-UGT2B17-transfected Ishikawa cells compared with control cells. However, there was no significant change in the number of invasive cells after transfection of si-UGT2B17. Therefore, these data suggest that UGT2B17 may play a role in apoptosis and the cell cycle but not invasion ability.
In order to further investigate the molecular mechanisms of UGT2B17 function, we used microarrays to screen for apoptosis-related genes and found altered expression of several genes in si-UGT2B17 transfectants and control cells. In the microarray data, five genes (BAX, LTBR, TNF, TNFRSF10A, CD27 and TRAF3) were upregulated in si-UGT2B17-transfected cells, whereas only Mcl-1 was downregulated. To confirm these data, we performed real-time RT–PCR to validate the microarray data. We also confirmed increased Mcl-1 protein levels by western analysis. Mcl-1 is an anti-apoptotic member of the Bcl-2 family and functions to suppress apoptosis (21). The function and sequence of Mcl-1 is very similar to Bcl-2 and both anti-apoptotic proteins share the ability to promote cell survival (22). In addition, Mcl-1 plays an important role in TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-resistant cancers (2125). Usually TRAIL death receptor signaling leads to increased apoptosis and is useful in cancer therapy (26,27). However, the therapeutical potential is limited because TRAIL resistance can occur through upregulation of FLIP or through an increase in anti-apoptotic proteins of the Bcl-2 family including Mcl-1 (28). In TRAIL-resistant cells, Mcl-1 inhibits BH3-only proteins (Bim, Puma and Bak) and inhibits apoptosis (2125,29). The combination of TRAIL with a multikinase inhibitor (sorafenib) has been used for the treatment of advanced renal cancer and liver cancer as the next step to TRAIL alone treatment (30,31). This combination therapy has been successfully used in other cancers (3234). The Raf–MAP kinase kinase–extracellular-signal-related kinase pathway is a target of sorafenib (mitogen activated protein kinase pathway). One of the mechanisms of apoptosis induction by sorafenib is Mcl-1 downregulation through reduced translation (2125). Llobet et al. (34) found that EC cell death triggered by sorafenib was mediated by downregulation of Mcl-1. In this study, Mcl-1 expression was downregulated in UGT2B17-depleted cells. Therefore, UGT2B17-depleted cells are similar to those treated with sorafenib, with alterations of the target genes of Mcl-1. As expected, the expression of Puma was increased in UGT2B17-knockeddown cells. As Akt and Mcl-1 have been shown to play an important role in TRAIL-induced apoptosis, we looked at Akt, phosphorylated-Akt and Mcl-1 expression (35). However, no relationship was found in western blot results suggesting that UGT2B17 itself may not affect the Mcl-1–Akt pathway.
We also examined Mcl-1 mRNA expression levels in EC tissues and matched adjacent normal endometrial tissues to see the relationship between UGT2B17 mRNA and Mcl-1 mRNA expression. Mcl-1 expression was increased in four of nine EC tissue samples. Among cancer tissue samples (n = 8) with increased UGT2B17 mRNA expression, Mcl-1 expression was also increased in four samples (50%) but not changed in two others. A tissue sample with decreased UGT2B17 expression in cancer similarly had decreased expression of Mcl-1. Thus, there may be a positive correlation between UGT2B17 and Mcl-1 mRNA expression. We also examined the relationship between UGT2B17 expression and clinical parameters such as stage and grade. However, we did not find a significant relationship. Since our sample number is relatively small, a larger study will be needed to look at the correlation between UGT2B17 expression and clinical parameters.
In conclusion, this is the first report to show that UGT2B17 and Mcl-1 expression is upregulated in EC tissues and that UGT2B17 knockdown inhibited cell growth and increased apoptosis in EC cells through Mcl-1 downregulation. However, additional studies will be required to reveal the exact molecular mechanisms involved in the regulation of Mcl-1 expression by UGT2B17. These findings also suggest that the expression level of UGT2B17 may be an endometrial tumor marker and silencing UGT2B17 may be beneficial as a therapeutic tool for EC. Since there are many UGT families, similar functional studies of these families have not been carried out. Therefore, the expression pattern of all UGT families in EC and adjacent normal tissues may be useful to predict them oncogenic or tumor suppressive effects.
Supplementary material
Funding
National Institutes of Health [R01CA108612, RO1CA101844 to R.D. (Principal Investigator)]; Yamada Science Foundation.
Supplementary Material
[Supplementary Data]
Acknowledgments
We thank Dr Roger Erickson for his support and assistance with the preparation of the manuscript.
Conflict of Interest Statement: None declared.
Glossary
Abbreviations
ECendometrial cancer
mRNAmessenger RNA
Mcl-1myeloid cell leukemia-1
PARPpoly ADP-ribose polymerase
RT–PCRreverse transcription–polymerase chain reaction
si-NCsi-negative control
TRAILtumor necrosis factor-related apoptosis-inducing ligand

1. Smith RA, et al. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J. Clin. 2007;57:90–104. [PubMed]
2. Nebert DW, et al. The role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nat. Rev. Cancer. 2006;6:947–960. [PubMed]
3. Liska DJ. The detoxification enzyme systems. Altern. Med. Rev. 1998;3:187–198. [PubMed]
4. Turgeon D, et al. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab. Dispos. 2003;31:670–676. [PubMed]
5. Mackenzie PI, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics. 2005;15:677–685. [PubMed]
6. Mackenzie PI, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 1997;7:255–269. [PubMed]
7. Duguay Y, et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res. 2004;64:1202–1207. [PubMed]
8. McGrath M, et al. Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet. Genomics. 2009;19:239–243. [PMC free article] [PubMed]
9. Lazarus P, et al. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann. N. Y. Acad. Sci. 2009;1155:99–111. [PMC free article] [PubMed]
10. Lazarus P, et al. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab. Rev. 2010;42:176–188. [PMC free article] [PubMed]
11. Nakamura A, et al. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos. 2008;36:1461–1464. [PubMed]
12. Harrington WR, et al. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006;147:3843–3850. [PubMed]
13. Saini S, et al. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res. 2009;69:7038–7045. [PubMed]
14. Hibner M, et al. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecol. Oncol. 2004;93:642–646. [PubMed]
15. Park J, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol. Biomarkers Prev. 2006;15:1473–1478. [PubMed]
16. Gallagher CJ, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol. Biomarkers Prev. 2007;16:823–828. [PubMed]
17. Hu DG, et al. Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. Mol. Pharmacol. 2009;76:425–439. [PubMed]
18. Sten T, et al. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab. Dispos. 2009;37:417–423. [PubMed]
19. Beaulieu M, et al. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J. Biol. Chem. 1996;271:22855–22862. [PubMed]
20. Wells PG, et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 2004;32:281–290. [PubMed]
21. Kang MH, et al. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009;15:1126–1132. [PubMed]
22. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 2009;66:1326–1336. [PubMed]
23. Vogler M, et al. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16:360–367. [PubMed]
24. Azmi AS, et al. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell. Physiol. 2009;218:13–21. [PMC free article] [PubMed]
25. Kim SH, et al. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 2008;68:2062–2064. [PubMed]
26. Zhang Y, et al. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol. Cancer Res. 2008;6:1861–1871. [PubMed]
27. Malhi H, et al. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene. 2006;25:7333–7335. [PubMed]
28. Hall MA, et al. Clearing the TRAIL for cancer therapy. Cancer Cell. 2007;12:4–6. [PubMed]
29. Ricci MS, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007;12:66–80. [PubMed]
30. Stadler WM, et al. ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116:1272–1280. [PubMed]
31. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J. Gastroenterol. 2009;44:136–141. [PubMed]
32. Huang S, et al. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol. Cancer Ther. 2010;9:742–750. [PubMed]
33. Blumenschein GR, Jr, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol. 2009;27:4274–4280. [PubMed]
34. Llobet D, et al. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur. J. Cancer. 2010;46:836–850. [PubMed]
35. Chen W, et al. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol. Pharmacol. 2010;77:416–423. [PubMed]
Articles from Carcinogenesis are provided here courtesy of
Oxford University Press